Funding for this research was provided by:
National Institute on Drug Abuse (R25DA035692)
National Center for Advancing Translational Sciences (5KL2TR002387-02)
Received: 11 July 2019
Accepted: 30 January 2020
First Online: 18 February 2020
Ethics approval and consent to participate
: The research activities described above were reviewed and approved by the Institutional Review Board (IRB) #1 on 7/18/2018 at Rush University Medical Center (RUMC) in accordance with the Federal Regulations found at 45 CFR 46 and 21 CFR 50 and 56 and any other governing regulations or subparts. Research participants age 16 provided written informed consent to participate in the research study—where participants age 15 written informed assent and their legal guardian provided written informed consent. All consent/assent documents were reviewed and approved by the Rush IRB and were in compliance with Rush policy, Federal regulations and Good Clinical Practices (GCP).
: Not applicable.
: The authors declare that they have no competing interests.